Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ARWR - Arrowhead Pharmaceuticals, Inc.
Market Cap 3.52B P/E - EPS this Y -144.30% Ern Qtrly Grth -
Income -538.64M Forward P/E -13.24 EPS next Y 10.00% 50D Avg Chg -6.00%
Sales 19.65M PEG -0.57 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 7.89 EPS next 5Y 7.33% 52W High Chg -32.00%
Recommedations 2.20 Quick Ratio 4.49 Shares Outstanding 124.32M 52W Low Chg 43.00%
Insider Own 4.47% ROA -40.72% Shares Float 110.46M Beta 0.97
Inst Own 80.46% ROE -151.84% Shares Shorted/Prior 9.05M/10.45M Price 32.97
Gross Margin 100.00% Profit Margin - Avg. Volume 906,422 Target Price 47.29
Oper. Margin -2,785.05% Earnings Date Nov 27 Volume 876,899 Change -2.11%
Healthcare | Biotechnology | United States
About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc. News
11/18/24 Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
11/18/24 Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
11/05/24 Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
11/04/24 Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
11/01/24 Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
10/14/24 Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10/09/24 Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ...
09/24/24 Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand
09/23/24 With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners
09/23/24 Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
09/11/24 FDA grants breakthrough therapy status to Arrowhead’s plozasiran
09/10/24 ARWR: PALISADE Phase 3 Results Published in NEJM…
09/10/24 Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
09/03/24 Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug
09/03/24 Arrowhead to file NDA after pivotal rare disease trial meets all endpoints
09/02/24 Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
08/22/24 ARWR: Two Obesity Assets to Enter the Clinic in 2025…
06:30 AM Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
08/16/24 Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance
08/15/24 Arrowhead announces push into obesity space with two gene therapies
ARWR Chatroom

User Image pcstock12 Posted - 6 hours ago

$ARWR This stock has been going down every year since it reached 90s.. The pipelines keep increasing but still no product...Have not posted in here for few years...

User Image Mattie2 Posted - 9 hours ago

$ARWR

User Image Mattie2 Posted - 9 hours ago

$ARWR If this turd drops to 15….. I just may buy 2 shares back. I can’t loose but $30. 😆😁😂🤣 Such a horrendous shame!! 4- 5 years ago no way I would have thought ARWR would EVER be $18 bucks now. I figured $300 but , I also thought they would be selling a drug by now. I do remember though…..a mouse committing suicide under the watchful eye of ARWR. Caused quite a 💩storm on share prices.

User Image skeezbag Posted - 15 hours ago

$ARWR looks like everyone in London loved what Ionis and Alny had to say but dog shit for the Rolex man

User Image ohkanby Posted - 19 hours ago

$ARWR still waiting for that partnership or licensing of non-core asset… come on CA, try to impress me.

User Image skeezbag Posted - 19 hours ago

$ARWR so it takes 3-4% upside in the rnai sector for arrowhead to not go down. Got it

User Image Mattie2 Posted - 21 hours ago

$ARWR DAAAAAAANG!!!!!!!!!

User Image TheChosenWon Posted - 21 hours ago

$ARWR look for this next leg lower to be very swift. $15 by Xmas easily

User Image QHD Posted - 1 day ago

$ARWR Does anyone know what the PDUFA date is for the NDA? TIA

User Image Stephen2437 Posted - 1 day ago

$ARWR any other bio tech would have had a nice day after their first NDA. Not this. Not surprised too which is sad.

User Image skeezbag Posted - 1 day ago

$ARWR close below 18.40 at all in the near future $15 within sight. Stock continues to linger at lows almost every day and hang within pennies of more bearish scenarios. It's actually quite remarkable how bearish the print is every day. Even on up days

User Image TheChosenWon Posted - 1 day ago

$ARWR now that the nothing burger NDA has passed, what's taking this lower next?

User Image skeezbag Posted - 1 day ago

$ARWR rumor has it shareholders get to pick an office at the empty Verona building

User Image Waitwhat Posted - 1 day ago

$ARWR This turd is why the market hates biotech.

User Image Pantherfan7979 Posted - 2 days ago

$ARWR Did our 16:04 trader retire?

User Image ILUVSPEWINGNONSENSE Posted - 2 days ago

$ARWR Ahead of schedule as always... 🤣

User Image johnnygogogo Posted - 2 days ago

$ARWR congratulations to the company on filing their first NDA today.

User Image Stocks4thought Posted - 2 days ago

@cb28 $ARWR They did it with this one at $1.60-----------and she when above $90...................this girl has always been a shuttlecock ---------------------back/forth/steam rolled etc.

User Image Kgoose Posted - 2 days ago

$ARWR we will continue to be the Rodney Dangerfield of bio’s, other bio’s with one drug, would have a significant jump, not ARWR, this speaks volumes that the board needs to address. If you think the cash burn is high now, if drug is approved, they dont have the capital to hire and train a sales team, they desperately need a cash infusion. Yippee for the NDA but with so many missteps by mgmt, the damage has been done.

User Image skeezbag Posted - 2 days ago

$ARWR now queue the post NDA sell off. We still have the post drug approval sell off

User Image skeezbag Posted - 2 days ago

$ARWR the bots don't even show up

User Image LeftyT Posted - 2 days ago

$ARWR I was able to grab a few more shares in the 18's this morning, but my LO did not completely fill before it bounced up into the 19 area. Still fishing for a few more cheap shares here.

User Image Lolobel Posted - 2 days ago

$ARWR nda 🙌🏻💥

User Image Scanners_Free Posted - 2 days ago

$ARWR News on main watch for today

User Image TheChosenWon Posted - 5 days ago

$ARWR BEAUTIFUL price action today. The NDA filing is not happening this year, and I'll bet any amount it's not filed in 1H 2025. Ionis drug is superior and first to market anyway, so NDA is actually irrelevant.

User Image skeezbag Posted - 5 days ago

$ARWR maybe company should make vaccines. We'd be down less

User Image FUDBusterzz Posted - 5 days ago

$ARWR is that 13g filing yesterday for an offering? Hedge fund ownership at .0001 cents a share

User Image ohkanby Posted - 5 days ago

$ARWR is this happening because of “Bidenomics” also? Asking for a friend.

User Image ponderevo Posted - 5 days ago

$ARWR I really enjoy not owning this name

User Image Jschwarma Posted - 5 days ago

$ARWR Closed at 21.41 yesterday….18.90 today. WTF i get some panic for BPs but why is this down 12% and staying. Insanity. Did something leak?

Analyst Ratings
RBC Capital Outperform Sep 26, 24
Cantor Fitzgerald Overweight Sep 9, 24
HC Wainwright & Co. Buy Sep 5, 24
HC Wainwright & Co. Buy Sep 3, 24
B. Riley Securities Buy Aug 12, 24
HC Wainwright & Co. Buy Jul 23, 24
Chardan Capital Buy Jul 17, 24
HC Wainwright & Co. Buy Jul 5, 24
Chardan Capital Buy Jun 26, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Sell 32.44 57,499 1,865,268 3,715,048 02/02/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Option 14.54 57,499 836,035 3,772,547 02/02/24
Hamilton James C Chief Discovery/Tran.. Chief Discovery/Trans Medicine Jan 12 Sell 36.92 7,940 293,145 210,851 01/17/24
GIVEN DOUGLAS B Director Director Jan 11 Sell 38.16 2,911 111,084 129,711 01/16/24
Waddill William D. Director Director Jan 11 Sell 38.2 3,934 150,279 47,870 01/16/24
Ferrari Mauro Director Director Jan 11 Sell 38.22 3,147 120,278 60,778 01/16/24
Vakiener Victoria Director Director Jan 11 Sell 38.36 4,720 181,059 32,001 01/16/24
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jan 04 Sell 33.89 74 2,508 136,501 01/08/24
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 04 Sell 34.89 16,104 561,869 440,600 01/08/24
San Martin Javier Chief Medical Office.. Chief Medical Officer Jan 04 Sell 34.93 8,303 290,024 198,497 01/08/24
Hamilton James C Other Other Jan 03 Sell 33.89 38,443 1,302,833 218,791 01/05/24
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 03 Sell 33.46 33,190 1,110,537 464,385 01/05/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 02 Sell 31 9,952 308,512 3,715,048 01/04/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 20 Sell 28.54 12,000 342,480 3,725,000 12/22/23
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 20 Sell 28.87 19,700 568,739 131,800 11/22/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 25 Sell 24.21 24,338 589,223 3,737,000 10/27/23
Vakiener Victoria Director Director Sep 28 Sell 26.33 1,550 40,812 21,734 10/02/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Sell 28.14 57,755 1,625,226 3,761,338 09/20/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Option 4.75 57,755 274,336 3,819,093 09/20/23
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jul 03 Sell 35.31 8,925 315,142 61,575 07/06/23
Hamilton James C Other Other Jun 30 Sell 35.53 3,000 106,590 188,484 07/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jun 27 Sell 36.20 15,000 543,000 381,704 06/29/23
GIVEN DOUGLAS B Director Director May 05 Sell 40.90 6,500 265,850 117,635 05/08/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Sell 39.38 104,928 4,132,065 3,761,338 05/05/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Option 2.01 104,928 210,905 3,811,338 05/05/23
OLUKOTUN ADEOYE Y Director Director Mar 03 Sell 32.65 11,350 370,578 7,867 03/06/23
GIVEN DOUGLAS B Director Director Feb 27 Sell 32.62 875 28,542 13,000 03/01/23
Waddill William D. Director Director Jan 09 Sell 30 3,200 96,000 28,950 01/11/23
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 05 Sell 37.39 15,000 560,850 413,375 01/06/23
Hamilton James C Other Other Jan 05 Sell 37.4 13,803 516,232 191,484 01/06/23
Hamilton James C Other Other Jan 03 Sell 39.05 10,338 403,699 145,287 01/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Dec 29 Sell 40.00 30,625 1,225,000 336,704 12/30/22
O'Brien Patrick General Counsel General Counsel Dec 21 Option 6.15 32,000 196,800 380,875 12/22/22
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 21 Sell 30.3 19,500 590,850 91,500 11/22/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 27 Option 30.99 40,624 1,258,938 3,468,314 09/29/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jul 07 Option 14.54 2,501 36,365 4,060,135 07/11/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Option 5.19 146,388 759,754 4,204,022 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Sell 51.7 146,388 7,568,260 4,057,634 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 07 Option 5.19 11,806 61,273 4,057,634 01/07/22
O'Brien Patrick General Counsel General Counsel Jan 05 Sell 62.59 32,500 2,034,175 348,875 01/07/22
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 05 Sell 62.41 40,000 2,496,400 464,005 01/06/22
Hamilton James C Other Other Jan 04 Sell 64.84 25,625 1,661,525 155,625 01/06/22
GIVEN DOUGLAS B Director Director Dec 28 Buy 66.37 655 43,472 109,868 12/29/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 68.28 60,000 4,096,800 3,219,022 12/17/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 20 Sell 65.96 65,000 4,287,400 3,279,022 10/22/21
O'Brien Patrick General Counsel General Counsel Feb 10 Option 5.22 90,000 469,800 383,375 02/10/21
O'Brien Patrick General Counsel General Counsel Feb 10 Sell 88.34 90,000 7,950,600 293,375 02/10/21
Hamilton James C Other Other Jan 15 Sell 81.4 10,000 814,000 126,250 01/15/21
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 12 Sell 81.01 13,038 1,056,208 444,005 01/12/21
O'Brien Patrick General Counsel General Counsel Jan 07 Sell 71.91 25,000 1,797,750 293,375 01/07/21